Facilities

located about 45 miles south of Houston

IsoTherapeutics Group is located about 45 miles south of Houston at 1004 South Velasco Street in Angleton, Texas. The facility consists of three buildings equipped with offices, R&D laboratories, cGMP production area, documentation room, shipping and receiving, controlled storage areas and an animal research laboratory.

R&D laboratories

Fully equipped with radiochemistry and analytical equipment

R&D laboratories

Fully equipped with radiochemistry and analytical equipment
Learn More

cGMP production area

Encompassing four controlled environment rooms and a large general lab area

cGMP production area

Encompassing four controlled environment rooms and a large general lab area
Learn More

animal research laboratory.

Equipped with a HEPA-filtered cabinet for housing athymic mice

animal research laboratory.

Equipped with a HEPA-filtered cabinet for housing athymic mice
Learn More
R&D Laboratories

Fully equipped with radiochemistry and analytical Equipment

radio-analytical equipment

Our radio-analytical equipment includes a variety of instrumentation including an automated NaI gamma counter along with several stand-alone NaI detectors, two germanium detectors for gamma spectroscopy, a liquid scintillation counter, an alpha spectroscopy system, dose calibrators, and many survey meters. A Siemens gamma camera allows for the capture and analysis of in vivo images.

Additional Equipment

Additional equipment includes a PerkinElmer Optima 5300 inductively-coupled plasma optical emission spectrophotometer, four chemical fume hoods, three laminar flow hoods, an HP 6890 Series GC with HP 7694 headspace sampler, an HP series 1100 HPLC with both UV and radiometric detection, an Agilent series 1200 Infinity HPLC with diode array UV and radiometric detection, an Agilent series 1200 Infinity HPLC with mass spec, variable wavelength UV and radiometric detection and a PerkinElmer Cyclone Plus Phosphor Imager, which provides autoradiography capabilities.

Biological Equipment

We have biological equipment for growing cell lines such as CO2 incubator, -80oC freezer, a certified Biological Safety Cabinet. Additional equipment includes lyophilizer, rotary evaporators, environmental chambers for product studies, steam autoclave, and various microscopes. A 96-well plate washer & reader allow us to efficiently set up ELISA assays and polyacrylamide gel electrophoresis allows for protein characterization.

cGMP Production Area

cGMP facility

The 3600 sq ft cGMP facility encompasses six controlled environment rooms and a large general lab area to assist customers with radiopharmaceutical manufacturing under the FDA guideline 21 CFR 11.

The facility is registered as a manufacturer with the FDA. The facility is equipped with the state-of-art equipment, such as class 5 lead-shielded isolators, laminar flow hoods, fume hoods, HPLC, LC-MS, autoclave, depyrogenation oven, and lyphollizer for making freeze-dried kits.

Vivarium Facility

animal research laboratory

The annex-building that houses our laboratory animals is equipped with a HEPA-filtered cabinet for housing athymic mice along with a PerkinElmer Wizard 3″ 1480 Automatic Gamma Counter to aid in bio-distribution studies. We own a variety of rodent cage types including metabolic cages for mice and rats. IsoTherapeutics is registered with the USDA as a Class R Research Facility under the Animal Welfare Act.

Facilities Galleries

Got a Project? Let's Schedule An Appointment

Telix Expands U.S. Development and Manufacturing Infrastructure with Acquisition of IsoTherapeutics

Melbourne (Australia) – 27 February 2024. Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire IsoTherapeutics Group, LLC (IsoTherapeutics), a specialty radiopharmaceutical development and bioconjugation firm, based in Angleton, Texas. Founded in 2005, IsoTherapeutics is a privately held, commercial-stage company, which provides radiochemistry and bioconjugation development and contract manufacturing services to many companies in the radiopharmaceutical industry, including Telix.
In line with Telix’s continued investment in the vertical integration of supply chain, manufacturing and development capabilities, the acquisition is expected to further enhance Telix’s in-house drug development capabilities. A key driver for the acquisition is to enable Telix to bring select aspects of its development programs in-house, with the goal of reducing cost and time to achieve technical milestones.
The acquisition will also expand Telix’s U.S. manufacturing footprint with a site that includes a GMP1 clean room and production infrastructure suitable for clinical use. The site also has extensive capacity to process a wide variety of therapeutic isotopes used in Telix’s development portfolio.